drugset / Trial / NCT01113333

Safety, Tolerability and Pharmacokinetics of SAR113945 Following Intra-articular Administration in Patients With Knee Osteoarthritis

NCT01113333 ↗

Phase 1 Completed 40 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary Objective: * Assess the safety and tolerability of single intra-articular doses of SAR113945 in patients with knee osteoarthritis. Secondary Objective: * Assess systemic exposure of SAR113945 following intra-articular delivery.

Timeline

Start
2010-04
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject SAR113945 Unknown — Other

Indications